| Project/Area Number |
14570737
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Kurume University (2003)
Gifu University (2002) |
|---|
Principal Investigator |
KOSAI Ken-ichiro Kurume University, Cognitive and Molecular Research Institute for Brain Disease, Professor, 高次脳疾患研究所, 教授 (90258418)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJIWARA Hisayoshi Gifu University Graduate School of Medicine, Department of Cardiology, Respiratory and Nephrology, Regeneration and Advanced Medical Science, Professor, 大学院・医学研究科, 教授 (80115930)
TAKAHASHI Tomoyuki Gifu University School of Medicine, Department of Gene Therapy and Regenerative Medicine, Assistant Professor, 医学部, 助手 (20332687)
KUNISADA Takahiro Gifu University Graduate School of Medicine, Department of Tissue and Organ Development, Regeneration and Advanced Medical Science, Professor, 大学院・医学研究科, 教授 (30205108)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,900,000)
Fiscal Year 2003: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2002: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Keywords | ES cell / Gene transfer / Vector / Congenital disease / Regenerative medicine / Adenoviral vector / Gene expression / Cardiomyocyte |
|---|
| Research Abstract |
<Aim> Regenerative medicine and gene therapy may be the most promising therapeutics for many of congenital diseases. In this respect, a development of a novel biotechnology and therapeutic strategy is crucially necessary. The present study develops the following technology; 1) control to induce a target cell from embryonic stem (ES) cell, 2) certain purification of ES-derived target cells.
<Results> 1. We developed a novel biotechnology that facilitated to certainly purify ES-derived target cells. 2. We developed a novel method that efficiently induced cardiomyogenic differentiation of ES cells using FGF-2 and BMP-2. 3. To further utilize this technology for future clinical application, we are doing research using human ES cells (our protocol was officially approved).
<Future plan> 1. We will clone important genes using purified ES-derived target cells. 2. We will assess the therapeutic potential of our strategy. 3. We will continue this research using human ES cells as well as mouse ES cell.
|
